Trial Profile

A phase 2a, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the efficacy, safety and pharmacokinetics of OBE022 added-on to atosiban, after oral administration in pregnant women with threatened spontaneous preterm labour

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jul 2021 According to an ObsEva media release, data from this study will be presented at the Society for Reproductive Investigation (SRI) 68th Annual Meeting
10 Jun 2021 Results presented in an ObsEva Media Release.
10 Jun 2021 According to an ObsEva media release, data announced at the Royal College of Obstetricians and Gynecologists (RCOG) Virtual World Congress 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com